Literature DB >> 20574423

Effects of long-term treatment for obstructive sleep apnea on pulse wave velocity.

Tsunenori Saito1, Tsunehiro Saito, Shigeyuki Sugiyama, Kuniya Asai, Masahiro Yasutake, Kyoichi Mizuno.   

Abstract

Continuous positive airway pressure (CPAP) treatment improves endothelial function and sympathetic activity in patients with obstructive sleep apnea (OSA). However, the long-term effects of CPAP on pulse wave velocity (PWV), which reflects arterial stiffness that is associated with cardiovascular events, have not been evaluated in OSA patients with or without hypertension (HT). In this study, 212 male OSA patients who had been receiving CPAP treatment for 2 years and were divided into two groups, those with HT (n=114) and those without (n=98), were studied. In both HT and normotensive (NT) patients, PWV decreased significantly over the first 6 months of treatment (P=0.005 and 0.010, respectively), before increasing gradually from 6 to 24 months. Body mass index (BMI), body weight, heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels decreased significantly in the HT group over the 2 years of CPAP treatment (P<0.001 for all). In contrast, only HR decreased significantly in the NT group over the 2 years of treatment (P<0.001). Multivariate regression analysis revealed that age (P=0.008), decreases in DBP (P<0.001) and HR (P<0.001) and higher initial levels of serum high-density lipoprotein-cholesterol (P=0.040) were independent factors related to changes in PWV over the 2 years of CPAP treatment in all patients. In conclusion, we found a significant decrease in PWV in both NT and HT patients after 6 months of CPAP treatment. In HT patients, long-term CPAP treatment significantly decreases blood pressure, which may contribute to explain the PWV improvement.

Entities:  

Mesh:

Year:  2010        PMID: 20574423     DOI: 10.1038/hr.2010.77

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

1.  Effects of mandibular advancement device treatment on arterial stiffness and glucose metabolism in patients with mild to moderate obstructive sleep apnea: a prospective 1 year study.

Authors:  Tea Galic; Josko Bozic; Natalija Ivkovic; Grgo Gunjaca; Tina Kurir Ticinovic; Zoran Dogas
Journal:  Sleep Breath       Date:  2015-05-01       Impact factor: 2.816

Review 2.  Cardiorespiratory interaction with continuous positive airway pressure.

Authors:  Martino F Pengo; Sara Bonafini; Cristiano Fava; Joerg Steier
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 3.  Effect of continuous positive airway pressure on arterial stiffness in patients with obstructive sleep apnea and hypertension: a meta-analysis.

Authors:  Xin Lin; Gongping Chen; Jiachao Qi; Xiaofang Chen; Jiangming Zhao; Qichang Lin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-09       Impact factor: 2.503

4.  CPAP therapy induces favorable short-term changes in epicardial fat thickness and vascular and metabolic markers in apparently healthy subjects with obstructive sleep apnea-hypopnea syndrome (OSAHS).

Authors:  Konstantinos Kostopoulos; Emmanouil Alhanatis; Konstantinos Pampoukas; Georgios Georgiopoulos; Andromahi Zourla; Athanasios Panoutsopoulos; Anastasios Kallianos; Lemonia Velentza; Paul Zarogoulidis; Georgia Trakada
Journal:  Sleep Breath       Date:  2015-07-30       Impact factor: 2.816

5.  Association between sleep-disordered breathing and arterial stiffness in heart failure patients with reduced or preserved ejection fraction.

Authors:  Satoshi Suzuki; Akiomi Yoshihisa; Yu Sato; Shunsuke Watanabe; Tetsuro Yokokawa; Takamasa Sato; Masayoshi Oikawa; Atsushi Kobayashi; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-Ichi Saitoh; Takafumi Ishida; Yasuchika Takeishi
Journal:  ESC Heart Fail       Date:  2018-02-20

Review 6.  State of the Art Review: Brachial-Ankle PWV.

Authors:  Hirofumi Tomiyama; Kazuki Shiina
Journal:  J Atheroscler Thromb       Date:  2020-05-23       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.